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esponsibility of InstAbstract Ginsenoside Rg1 (GR), a major bioactive compound of traditional Chinese medicine, such as
Panax ginseng or Radix Notoginseng, has been shown to exert neuroprotective effects against ischemic
stroke. However, pharmacokinetic studies have suggested that GR could not be efﬁciently transported
through the blood–brain barrier. The mechanism by which GR attenuates cerebral ischemic injury in vivo
remains largely unknown. Therefore, this study explored potential neuro-protective effects of GR through
its systemic metabolic regulating mechanism by using mass spectrometry–based metabolomic proﬁling.
Rats with middle cerebral artery occlusion (MCAO) were treated with GR intravenously. Their metabolic
proﬁles in serum were measured by gas chromatography coupled with mass spectrometry on 1 and 3 days
after MCAO. GR exhibited a potent neuro-protective effect by signiﬁcantly decreasing the neurological
scores and infarct volume in the MCAO rats. Moreover, 18 differential metabolites were tentatively
identiﬁed, all of which appeared to correlate well with these disease indices. Our ﬁndings suggested that
GR carries a therapeutic potential in stroke possibly through a feed-back mechanism by regulating
systematic metabolic mediation.
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Ischemic stroke, a complex devastating disease, is caused by a
drastic disruption of cerebral blood ﬂow that triggers a multistep
pathophysiological ischemic cascade sufﬁcient to cause metabolic
disorder or functional deﬁcit. Benchmark studies have reported
quite a few neuro-protective agents with moderate efﬁcacy in
stroke management. However, the treatment of stroke remains
considerably unsatisfactory as the performance of almost all neuro-
protective agents in the clinical treatment of patients with stroke
had been disappointing1–3. Therefore, new pharmacological stra-
tegies for stroke management are needed to improve its outcome
and elucidate the physiological mechanism of this disease.
Ginsenoside Rg1 (GR; Fig. 1), a panaxatriol saponin, is the
major active compound in Panax ginseng and Radix Notogin-
seng4, which are two distinguished herbs that have been used for
thousands of years in clinical treatment in China. Research has
shown that GR exerts neurotrophic and neuro-protective effects on
ischemic stroke5, and its possible mechanism has been attributed
to its anti-oxidative effects on neurons, anti-edema properties, and
regulation of various signaling pathways6,7. However, pharmaco-
kinetic studies have demonstrated that GR could neither be
efﬁciently transported through the blood-brain barrier nor be
efﬁciently distributed to reach its effective concentration in brain
tissue8. Therefore, the mechanism by which GR affects cerebral
ischemic injury in vivo remains largely unknown and warrants
further investigation.
Metabolomics has been used for identifying potential diagnostic
biomarkers, and elucidating mechanism for complex disease and
toxicity associated with the treatment9–11. Metabolomics can
comprehensively measure the metabolites present in the circula-
tion, which could reﬂect the balance between blood and the
internal environment of brain tissue. Yang et al.12 reported that
their comprehensive analysis of a wide range of metabolites in
various physiological states apparently showed promising perspec-
tives in complex disease, whereas Jiang et al.13 suggested that
metabolomics might effectively aid in the diagnosis of ischemic
stroke and prognostic estimation.
We hypothesized that there is a systemic feed-back regulating
mechanism, through which GR indirectly exerts its effects on
neurons. The results of this study further explain the neuro-
protective mechanism of GR on cerebral ischemic injury. In
addition, with the help of potential systemic metabolites in the
circulation screened and identiﬁed using gas chromatography
coupled with mass spectrometry (GC-MS) based on a metabolo-
mic approach, the present study was also to explore potential
nontargeted biomarkers for the diagnosis of ischemic stroke.Figure 1 Chemical structure of GR.2. Materials and methods
2.1. Animal care
The experimental protocol was approved by the Ethics Committee
for Animal Experimentation of Capital Medical University
(Beijing, China) and conformed to internationally accepted stan-
dards. Sixty male Sprague-Dawley rats (280–320 g) were supplied
by the Vital River Laboratories (Beijing, China) and housed under
controlled conditions with a 12-h light/12-h dark photoperiod, at
2172 1C, and with a relative humidity of 60%75% for at least 1
week before the experiment. They were allowed free access to a
standard rodent diet and tap water.
2.2. Chemicals and reagents
GR was purchased from Ronghe Technology Co., Ltd. (Z98%
purity, Shanghai, China). N-methyl-N-(trimethylsilyl)-triﬂuoroace-
tamide and trimethylchlorosilane were purchased from Sigma-
Aldrich (St. Louis, USA). Ribitol (internal standard) was pur-
chased from Sinopharm Chemical Reagent Corporation (Shanghai,
China), and 2,3,5-triphenyltetrazolium chloride was obtained from
Sigma-Aldrich.
2.3. Transient focal cerebral ischemia
Middle cerebral artery occlusion (MCAO) was induced using the
intraluminal suture method14,15. Brieﬂy, rats were anesthetized
using chloral hydrate (400 mg/kg); a 2.0 cm skin incision was
made in the ventral neck muscles. A 3–0 MCAO monoﬁlament
(Beijing Sunbio Biotech Co., Ltd.) was advanced to block the
origin of the MCA. Regional cerebral blood ﬂow (rCBF) was
monitored by a laser Doppler computerized main unit (Perimed
AB, Sweden). The MCAO was set up with rCBF sharp decreasing
to 20% of baseline level before ischemia; otherwise, animals were
excluded. Reperfusion was performed by withdrawing the mono-
ﬁlament after 120 min ischemia, and then wounds were closed.
During the surgery and reperfusion, rectal temperature was
maintained at 3770.5 1C by means of a heating blanket. The
mortality of the MCAO model is around 15%. A similar procedure
without MCAO was conducted in control rats.
2.4. Animal treatments
After MCAO, rats were randomly divided into the following
groups: sham operation (control); MCAO treated with water
(model); MCAO treated with 30 mg/kg GR per day (GR 30 mg/kg);
and MCAO treated with 60 mg/kg GR per day (GR 60 mg/kg). After
reperfusion for 2 h, rats were treated with GR intravenously twice daily
for 3 days. The control and model groups were treated with an equal
volume of saline.
2.5. Neurological function evaluation
The neurological function of the conscious rats was blindly
evaluated 1 day and 3 day after MCAO. A ﬁve-point scale
reported previously16 was carried out to evaluated the neurological
deﬁcit scores (score 0, no deﬁcit being observed; score 1, failing to
fully extend left forepaw; score 2, circling to the left side; score 3,
falling to the left; score 4, with no walking and consciousness
being depressed) by an observer who was blind to the group.
Figure 2 Protective effect of GR on cerebral ischemic injury. (A) Infarct images observed using 2,3,5-triphenyltetrazolium chloride staining on day
3 after MCAO (n¼10). (B) Signiﬁcant reduction in infarct volume in the GR 30 mg/kg treatment group and 60 mg/kg treatment group compared with
the model group consistent with the results predicted by the enter regression and stepwise models. (C) Neurological scores at 24 h after MCAO, the
scores of control group was zero, data not shown. nPo0.05; nnPo0.01.
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The animals were euthanized on day 3 after MCAO. Their brains
were collected and sliced into seven coronal sections with 2-mm
thickness each stained with 2% solution of 2,3,5-triphenyltetrazo-
lium chloride in saline at 37 1C for 30 min14,15.2.7. Sample collection and preparation
On day 1 and day 3 after MCAO, the rats were anesthetized by
ether inhalation after their treatment. Their blood was collected
from orbital venous and centrifuged at 1500 g for 10 min. Serum
was stored at 80 1C until use.
Thawed serum samples (100 μL) were spiked with the internal
standard (5 μL of 1 mg/mL ribitol) and mixed with acetone (200 μL)
by vortexing for 1 min. After incubation on ice for 10 min, the mixture
was centrifuged at 4 1C for 10 min at 10,000 g. The supernatant
(200 μL) was transferred to a GC vial and evaporated to dryness under
vacuum at 35 1C for approximately 4 h in a concentrator (Thermo
Speedvac Concentrator, USA). Derivatization was performed using
methoxyamine pyridine (35 μL; 15 mg/mL) at 70 1C for 1 h, followed
by N-methyl-N-(trimethylsilyl)triﬂuoroacetamide (35 μL) with 1%trimethylchlorosilane as the catalyst at room temperature (25 1C) for
1 h. Finally, n-heptane (100 μL) was added to dilute the solution after
the derivatization, and the supernatant was used for GC-MS analysis.2.8. GC-MS analysis
The system consisted of an Agilent 7683 Series mass spectrometer
(Electron ionization mass spectra were recorded at 70 eV and 2 scans/s.
Full-scan mass spectra were acquired from 60 to 600 m/z at the scan
rate of ﬁve times per second) coupled to an Agilent 6890 gas
chromatograph system (Agilent Technologies, Atlanta, USA). One
microliter of sample solution was injected in splitless mode to a ZB-
5MS column (30 m 250 μm 0.25 μm) with helium as the carrier
gas at the ﬂow rate of 0.8 mL/min. The injector temperature was set at
270 1C. The temperature of the ion source was adjusted to 230 1C,
whereas that of the quadrupole was set at 150 1C. The initial
temperature of the column was maintained at 70 1C for 5 min. It
was then increased at the rate of 10 1C/min to 90 1C where it was held
for 1 min, at 5 1C/min to 140 1C for 2 min, at 12 1C/min to 182 1C for
2 min, and then at 2 1C/min to 225 1C for 3 min. Subsequently, the
temperature was increased to 300 1C at the rate of 15 1C/min and held
for 5 min. The peaks of interest were identiﬁed by searching the NIST
Figure 3 Metabolic proﬁles in the circulation of MCAO and control rats (n¼10). (A) Typical total ion current chromatograms of rat serum from
the control and model groups. The numbered peaks represent the metabolites in panel B. (B) Structural information on the differential metabolites
identiﬁed between the control and model groups.
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standards.2.9. Statistical analysis
Statistical analysis was performed in SPSS version 11.5 statistical
software (SPSS Inc.). Data were expressed as mean7SEM. For a
normal distribution, student's t test was used to compare between
two groups, whereas one-way ANOVA was conducted for
comparisons of multiple groups, followed by Fisher's least
signiﬁcant difference test; while non-parameter analysis was used
for non-normal distribution. Multiple linear regression analysis
was performed to determine the relationship between infarct
volume and the metabolites during ischemia, and the predicted
and observed infarct volumes in the control group were then
compared using analysis of covariance. In addition, principalcomponent analysis (PCA) was performed with SIMCA-P 11.5
(Umetrics AB, Umea, Sweden).3. Results
3.1. Protective effect of GR on cerebral infarction
Neurological deﬁcit scores and infarct volume with or without GR
treatment were measured to examine the inﬂuence
of GR on cerebral ischemic injury. The animals were divided
into four groups: control, model, GR of 30 mg/kg, and GR of
60 mg/kg. A remarkably decreased pale-colored region was
observed in the GR-treated groups compared with the model
group (Fig. 2A). The cerebral infarct volumes were signiﬁ-
cantly reduced after GR treatment compared with model treatment,
which was consistent with the results predicted by the enter
regression and stepwise models (Fig. 2B). Neurological functional
Figure 4 Correlation between differential metabolites and cerebral
infarct injury (n¼10). (A) Score plots of the PCA map for the control
group (▼) and model group (♦) on day 1 (open symbols) and day 3
(ﬁlled symbols). (B) Pearson's correlation coefﬁcients of the 18
differential metabolites and neurological deﬁcit scores on day 1. (C)
Pearson's correlation coefﬁcients of the 18 differential metabolites and
infarct volume on day 3. X1, X2, X3, …, X18 represent the
corresponding metabolites identiﬁed in Fig. 2. *Po0.05; nnPo0.01.
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which could be prevented by GR treatment (Fig. 2C). Compared
with the model group, signiﬁcant reduction in the neurological
deﬁcit scores were observed in the GR 60 mg/kg group on day 1,
and both GR treatment group on day 3. These results suggested
that GR could prevent cerebral ischemic injury with intravenously
treatment.
3.2. Serum metabolic proﬁles of control and MCAO rats
Representative total ion current chromatograms of sera from the
control and model (cerebral infarction) groups are shown in
Fig. 3A. Forty-ﬁve endogenous metabolites in serum wereidentiﬁed by the NIST mass spectra library. According to the
peak area ratios of the metabolites to the internal standard (ribitol),
18 metabolites were changed signiﬁcantly (Po0.05) compared
with the control group on day 1 or day 3. The chemical structures
of these 18 differential metabolites are shown in Fig. 3B.
3.3. Association between differential metabolites expression and
cerebral infarct injury
PCA was carried out to evaluate the capability of the GC-MS-
based metabolomic approach to differentiate the model group from
the control group. The PCA score plots (Fig. 4A) showed marked
separation between these groups on days 1 and 3, when time-
dependent proﬁle separations could also be observed in the
model group.
The correlation coefﬁcients between neurological deﬁcit
scores (Fig. 4B) and infarct volume (Fig. 4C) with the 18
differential metabolites were listed. Of these metabolites, X3
and X7 were found to positive and negative correlate with
neurological scores on day 1, respectively, whereas X6 and X12
were found to positive and negative correlate with infarct volume
on day 3, respectively.
3.4. Prediction of infarct volume using metabolic proﬁling
Multiple linear regression analysis was performed to build a
prediction model of infarct volume based on the differential
metabolites. As shown in Fig. 5A, a linear regression model
exhibited a signiﬁcantly high R2 value (0.871; Po0.05) using the
enter selection method with all factors entered. The enter model
was further validated by covariance analysis of predicted and
observed infarct volumes in MCAO rats (Po0.05) (Fig. 5B),
indicating that the infarct volume might be predicted using this
model with these metabolites.
A stepwise regression selection procedure was performed to
build a compact model (Fig. 5C) with two factors ﬁnally entered
(R2¼0.678; Po0.05) to avoid high R2 values using the enter
procedure due to overﬁtting with a high number of factors. As
shown in Fig. 5D, the model was validated by covariance analysis
using the infarct volume in MCAO rats as the test set (Po0.05).
These results suggested that metabolite X4 (Ethanedioic acid) and
X18 (Cholesterol) are potential major biomarkers for the prediction
of infarct volume and that all the metabolites might be systemic
nontargeted biomarkers for the prediction of cerebral ischemic
injury.
3.5. Intervention of GR in the differential metabolites in the
circulation
Differential metabolites, which have been previously conﬁrmed to be
correlated with the evolution of ischemic injury, were used to
investigate the potential neuro-protective mechanism of GR. Good
classiﬁcations were observed in the PCA score plots for days 1 and 3
(n¼10) (Fig. 6A). The model group was distributed on the bottom
right side, well separated from the control group on the top left side.
Sample plots from the modelþGR-treated groups were moved from
the bottom right side to the top left side in a time- and dose-dependent
fashion, indicating that the differential metabolites in the circulation
after MCAO could be regulated back to normal levels.
As shown in Fig. 6B, changes in the percentages of relative
peak area ratios in the control group were calculated and compared
Mingbao Lin et al.282with those in the model group to evaluate the recovery condition
of each metabolite after GR treatment. With GR 30 mg/kg
treatment, X3 and X8 metabolites were signiﬁcantly regulated
back to their normal status on days 1 and 3, respectively.
Meanwhile, with GR 60 mg/kg treatment, X6 and X16 metabolites
were regulated signiﬁcantly back on days 1 and 3, respectively.4. Discussion
Stroke is the leading cause of disability and second major cause
of death in China17,18. However, until now, its treatment remains
considerably unsatisfactory. Traditional Chinese medicines have
been practiced in stroke prevention and management for thou-
sands of years19. GR, an active constituent of protopanaxatriol
found in traditional Chinese medicine agents, such as Ginseng
and Radix Notoginseng, is known to have potent neuro-
protective effects against brain injury20. Most experimental
studies have focused on neurons as neuro-protective targets of
GR5,21,22. However, research has also demonstrated that GR is
poorly distributed to the brain because it could not be efﬁciently
transported through the blood-brain barrier and reach theFigure 5 Prediction model for cerebral infarction built based on the diffe
using the enter selection method (n¼30). (B) Results of the covariance an
the predicted infarct volume calculated using the equation in panel A (n
(D) Results of the covariance analysis of predicted and observed infarct vol
the equation in panel C (n¼10).effective concentration in brain tissue8. Accordingly, whether
GR could be effectively distributed into brain tissue and directly
carry out potent neuro-protective effects on neurons remains
unclear. We thus hypothesized that the neuro-protective effects of
GR could be attributed to a potential systemic regulating
mechanism. Following cerebral infarction, the microenvironment
of blood circulation is disturbed by central nervous system
disorders, which might react by affecting the injury course of
brain tissue. Then small molecule metabolites transported
through the blood-brain barrier, the degradation of the micro-
environment of the brain enhances cerebral tissue damage, which
showed that the metabolites were signiﬁcantly correlated with
cerebral damages23.
It has been shown that many small molecule metabolites in the
circulation system may contribute to cerebral ischemic disorders13.
In this study, GC-MS-based metabolomic proﬁling was performed
to screen differential metabolites in the circulation after MCAO.
Eighteen metabolites in serum were tentatively identiﬁed. With
PCA, these metabolites can clearly distinguish MCAO rats from
the controls. Meanwhile, the multivariate linear regression model
showed that these metabolites signiﬁcantly correlated with the
neurological deﬁcit scores on day 1 and with the infarct volume onrential metabolites using multiple regression analysis. (A) Model built
alysis of predicted and observed infarct volumes in MCAO rats, with
¼10). (C) Model built using the stepwise selection method (n¼30).
umes in MCAO rats, with the predicted infarct volume calculated using
Figure 6 Intervention of GR in the differential metabolites in the circulation after MCAO (n¼10). (A) PCA score plots of differential
metabolites in serum on days 1 and 3. (B) Heat maps indicating the recovery condition of the differential metabolites after GR treatment on days 1
and 3. The color intensity represents changes in the percentages of relative peak area ratios compared with the control. Green indicates decreased
expression, whereas red signiﬁes increased expression. #Po0.05; ##Po0.01, compared with the model group.
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injury process. Therefore, these differential metabolites might be a
potential systemic biomarker for cerebral ischemic injury predic-
tion and potential systemic targets for cerebral injury regulation.
This study has provided preliminary evidence that GR could
protect against cerebral ischemic injury, including the reductions
in neurological deﬁcit scores and infarct volume. We found that
the differential metabolites in the circulation after MCAO might be
regulated back to their normal levels after GR treatment. Further-
more, the infarct volumes predicted by the enter and stepwise
prediction models were consistent with the observed values. These
ﬁndings suggested that the neuro-protective effects of GR are
correlated with regulating the imbalance of metabolites to a normal
status in the circulation. However, further studies are needed in
order to determine whether the changes in serum metabolite levels
are mechanistically linked to the neurological changes.
In conclusion, by using an integrated analytical approach based
on GC-MS, this study found preliminary data in support of the
idea that the neuro-protective effects of GR on cerebral ischemic
injury might be attributed to a potential indirect systemic regulat-
ing mechanism, associated with anaerobic glycolysis, the tricar-
boxylic acid cycle, the urea cycle and the amino acid metabolism.
The differential metabolites detected in this study might be a
potential systemic biomarker for the prediction of cerebral infarct
injury. These ﬁndings may eventually enhance the current under-
standing the pharmacological targets and mechanism of GR on
cerebral infarction. Further research will be carried out to support
the above-described hypothesis.Acknowledgments
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